Learn more about us
My name is Tarun Chandra and I am the Founder and Editor of the newsletter service. The objective is to empower investors with portfolio products that aim to outperform the market consistently over time by leveraging quantitative techniques, systematic investing, and compounding.
Graycell Advisors is a publisher of stock newsletters, like Prudent Small Cap, Prudent Biotech, and Prudent Healthcare. More can be learned here.
As someone who has worked as an Analyst on Wall Street for many years and on Main Street in Corporate Strategy and Finance roles at technology services companies, I understand the mechanics of investing and corporate performance. I have been building quantitative investing models for many years. My academic graduate background is in Finance and also in Systems Analysis & Design. A lengthier sit-back-and-read type of background of the journey is presented in the section on Systematic Investing.
If you subscribe to the newsletters, I hope we can contribute to your investment objectives and build investment wealth over time. If you are an asset manager or institution who will like to discuss a dedicated product, please contact us by using the contact form or writing to us at support@GraycellAdvisors.com
Graycell Advisors, and its affiliates, officers, employees, families, and all other related parties, collectively referred to as ‘Graycell’ and/or ‘we,’ is a publisher of financial information, such as the Prudent Small Cap, Prudent Biotech, and Prudent Healthcare newsletters. We are not a Registered Investment Advisor (RIA). Historical performance figures provided are hypothetical, unaudited, and based on our proprietary analysis and system performance, back-tested over an extended period. Hypothetical or simulated performance results have limitations, and unlike an actual performance record, simulated results do not represent actual trading and consequently do not involve the financial risk of actual trading. The performance results obtained are intended for illustrative purposes only. No representation is being made that any account will or is likely to achieve profit or losses similar to those shown. Past performance is not indicative of future results, which may vary. All stock and related investments have a degree of risk, which can result in a significant or total loss. In addition, the biotech industry and small caps are characterized by much higher risk and volatility than the general stock market. Information contained herein is general and does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual investors. If you decide to invest in any of the stocks of the companies mentioned in the newsletters, samples, alerts, etc., sent to you or available on our websites, you can and may lose some or all of your investment. You alone are responsible for your investment decisions. Use of the information herein is at one's own risk. We are simply sharing the results of our model. Nothing should be construed as a recommendation or an offer to buy or sell any securities, and we are not liable nor do we assume any liability or responsibility for losses incurred as a result of any information provided or not provided or not made available on time, herein or on our website or using any other medium. We cannot guarantee the accuracy and completeness of any information furnished by us. We may or may not have existing positions in the stocks mentioned in our reports. Our models are proprietary and/or can be licensed and can be changed or revised based on our discretion at any time without any notification. Subscribers and investors should always conduct their due diligence with any potential investment and consider obtaining professional advice before making an investment decision.
© Graycell Advisors. All rights reserved. Any act of copying, reproducing, or distributing this newsletter whether wholly or in part, for any purpose without the written permission of Graycell Advisors is strictly prohibited and shall be deemed to be copyright infringement.